You searched for "screening"

634 results found

The BSoT buddy scheme at BAUS 2023: a new initiative for fostering international relationships

The BSoT committee at BAUS, many of whom where involved with the inaugural buddy scheme. The buddy background By Nicholas Boxall, Specialty Registrar, Cambridge University Hospitals NHS Foundation Trust; Immediate Past Chair of BSoT. The BAUS Section of Trainees (BSoT)...

In conversation with Mary Garthwaite

We were delighted to chat with Mary Garthwaite, former Consultant Urological Surgeon and Chair of The Urology Foundation, the UK’s only charity representing all urological cancers and conditions. Can you tell us a little bit about what led you into...

An overview of non-surgical treatment options for Peyronie’s disease

Peyronie’s disease (PD) is a therapeutic challenge despite the availability of several non-surgical and surgical options. Very few of these options are supported by good quality evidence according to the current American and European guidelines [1-3]. The period of plaque...

Prostate cancer nurse specialist shortage: a view from the coal face

Prostate Cancer UK recently reported that there is an impending crisis for men with prostate cancer, simply because the number of nurse specialists available is insufficient for their needs [1]. Background As has been widely reported, the incidence of prostate...

The management of renal calculi – Pt 2

Renal calculi can be managed according to four treatment options: conservative management, extracorporeal shock wave lithotripsy (ESWL), flexible ureterorenoscopy (FURS) and percutaneous nephrolithotomy (PCNL). Having addressed conservative management and ESWL in the last edition of Urology News, the second article...

New £1.9M drug trial could delay relapse for prostate cancer patients

A new drug could keep cancer under control for longer for men with advanced prostate cancer and will be tested in a new trial funded with £1.9 million from Prostate Cancer UK. Current treatments, like chemotherapy or hormone-targeting therapies, can...

An update on mobile apps in urology

Amongst the plethora of mobile applications, there are some essential applications for practising urologists, urologists in training and patients. In this month’s digital review, we highlight some essential applications. Mobile office apps Maintaining a virtual office is key to keeping...

Artificial intelligence in bladder cancer diagnostics

Bladder cancer (BCa), ranking as the 10th most common cancer worldwide, poses a significant health burden with high morbidity and mortality [1]. Timely tumour detection and accurate evaluation are crucial for effective management, as the prognosis is dependent on the...

What’s new in post prostatectomy incontinence?

With an ageing population, the number of men being diagnosed with prostate cancer each year is steadily rising. With more specific investigations, such as multiparametric magnetic resonance imaging (MpMRI) and transperineal biopsies, the number of cases diagnosed at an earlier...

A novel approach to surgical management of the nutcracker phenomenon

The nutcracker phenomenon is defined as compression of the renal vein between the aorta and superior mesenteric artery and can present with loin pain, haematuria and a left-sided varicocele with treatment options including left renal vein transposition, superior mesenteric artery...

Phase two trial of SAbR for primary RCC

A study focused on stereotactic ablative radiotherapy (SAbR) as a treatment for primary renal cell carcinoma (RCC) has yielded significant findings. The primary objective of the study was successfully met, demonstrating a 94% local control rate at one year among...

New ultrasound imaging technique reliably spots prostate cancer, initial patient trial reveals

A groundbreaking new imaging approach developed by researchers at Heriot-Watt University has shown ‘extremely encouraging’ results in early-stage clinical trials on prostate cancer at the Western General Hospital in Edinburgh, Scotland. The ongoing clinical trial demonstrated an initial 94% sensitivity...